SCHEMBL3252902

SCHEMBL3252902

Cc1cc(C)cc(S(=O)(=O)N(CC(N)=O)c2ccc(Cl)cc2Cc2c(F)cccc2F)c1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.40
PTGER1 P34995 2/20 0.39
THRB P10828 1/20 0.39
KEAP1 Q14145 3/20 0.39
NFE2L2 Q16236 3/20 0.39
PSEN1 P49768 3/20 0.38
PSEN2 P49810 3/20 0.38
APH1B Q8WW43 3/20 0.38
NCSTN Q92542 3/20 0.38
APH1A Q96BI3 3/20 0.38
PSENEN Q9NZ42 3/20 0.38
MCOLN3 Q8TDD5 2/20 0.38
POLB P06746 1/20 0.38
C5AR1 P21730 1/20 0.37
PKM P14618 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
HCRTR2 O43614 1/20 0.36
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8273297 0.90 POLB (0.36) HPGDPTGER1THRBKEAP1NFE2L2
SCHEMBL13357747 0.89 PTGER1 (0.44) PTGER1THRBMCOLN3POLBMEN1
SCHEMBL8275165 0.89 KEAP1 (0.48) HPGDPTGER1KEAP1NFE2L2PSEN1
SCHEMBL8273340 0.88 KEAP1 (0.48) HPGDKEAP1NFE2L2MCOLN3POLB
SCHEMBL3256162 0.86 HCRTR2 (0.39) THRBKEAP1NFE2L2MCOLN3POLB
SCHEMBL3251585 0.86 MAPT (0.41) HPGDPTGER1THRBKEAP1NFE2L2
SCHEMBL8272221 0.86 KEAP1 (0.46) HPGDPTGER1KEAP1NFE2L2PSEN1
SCHEMBL3256512 0.85 PKM (0.56) HPGDKEAP1NFE2L2MCOLN3POLB
SCHEMBL8273309 0.85 PKM (0.48) HPGDKEAP1NFE2L2MCOLN3POLB
SCHEMBL8273864 0.85 PKM (0.48) HPGDKEAP1NFE2L2MCOLN3POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 HPGD 4662/4885PTGER1 4534/4885THRB 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.